Focused On-demand Library for rRNA N6-adenosine-methyltransferase METTL5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NRN9

UPID:

METL5_HUMAN

Alternative names:

Methyltransferase-like protein 5

Alternative UPACC:

Q9NRN9; D3DPC9; Q9NVX1

Background:

The rRNA N6-adenosine-methyltransferase METTL5, also known as Methyltransferase-like protein 5, plays a pivotal role in the post-transcriptional modification of 18S rRNA. It specifically methylates the 6th position of adenine in position 1832, a modification crucial for the decoding center's function in translation and embryonic stem cells' pluripotency and differentiation.

Therapeutic significance:

Given its involvement in Intellectual developmental disorder, autosomal recessive 72, characterized by severe intellectual disability and microcephaly, METTL5 presents a promising target for therapeutic intervention. Understanding the role of METTL5 could open doors to potential therapeutic strategies.